Appointments Reflect Diversity of the Association’s Membership
Pennsylvania Bio, the statewide trade association representing the Commonwealth’s life sciences industry, announced recently the appointment of ten new members to its Board of Directors:
“On behalf of the Pennsylvania Bio Board of Directors, we are honored to welcome ten industry leaders whose expertise and dedication will be essential assets to the Board of Directors and the Association,” said Robert Bazemore, Chair of the Pennsylvania Bio Board of Directors and Vice President, Global Strategic Marketing of Ethicon, Inc.
“The addition of these individuals to the Board continues our ongoing effort as a trade association to ensure Pennsylvania remains a global leader in the life sciences industry,” added Pennsylvania Bio President and CEO Christopher Molineaux.
Armando Anido was most recently Chief Executive Officer and Director of NuPathe, Inc., a publicly traded biopharmaceutical company focused for the company and ultimately selling NuPathe to TEVA for $160M in upfront cash and CVRs worth up to another $140M. Mr. Anido has more than thirty years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He is currently a member of the board of directors of Respira Therapeutics, Inc. Mr. Anido received his BS in Pharmacy and his MBA in Marketing and Finance from West Viriginia University.
Stephen Allan is currently Vice-President of Marketing and Communications of Unilife Corporation, a U.S. based developer and supplier of injectable drug delivery systems. Mr. Allan oversees activities relating to communications, corporate and commercial marketing, public relations and government affairs. Mr.Allan has more than twenty years of public advocacy and marketing experience in the U.S. and Australia. Mr. Allan received a B.A. in Communications from Australia’s most reputable university for media professionals.
Mattew J.Gantz is the Executive Vice President, U.S. at BTG International an international specialty healthcare company with a focus in interventional Medicine and Specialty Pharmaceuticals. The company is growing via diversified revenue streams generated by a mix of interventional oncology, interventional vascular and acute care products, as well as royalties from licensed products. In his current role at BTG he is responsible for its global Specialty Pharmaceutical and Interventional Clot Therapy business as well as administrative oversight of all US operations. With more than twenty years of experience in the life science industry, Mr. Gantz brings experience in both startup operations and developing and implementing strategies to build growing, sustainable multi-national businesses. He also serves on the Board of Swedish Orphan Biovitrum, a publically traded rare diseases specialty company based in Sweden. Mr. Gantz received a BA in History from Princeton University, an MBA from Harvard Graduate School of Business Administration and served as an infantry officer in the United States Marine Corps.
Philip Hosbach currently holds the position of Vise President, New Products and Immunization Policy at Sanofi Pasteur. His responsibilities include oversight of immunization policy development and coordination of Sanofi Pasteur relations with Federal and State Government officials. Mr. Hosbach also serves as Chairman for Sanofi Pasteyr’s Philanthropy Steering Committee and is Chairman of the Sanofi Pasteur Employee Political Action Committee. Mr. Hosbach acts as Sanofi Pasteur’s principle liaison with CDC, and coordinated Sanofi Pasteur’s global efforts in responding to the H1N1 pandemic in 2009-10. Mr. Hosbach is a graduate of Lafayette College.
Dr. Philip Johnson currently serves as Chief Scientific Officer, Executive Vice President, and Director of the Research Institute at the Children’s Hospital of Philadelphia. He also holds the Edmond F. Notebaert Chair in Pediatric Research and is a Professor in the Department of Pediatrics at the University of Pennsylvania School of Medicine. In his role as Chief Scientific Officer, Dr. Johnson oversees the research enterprise at Children’s Hospital that supports over 2,000 faculty and staff engaged in a wide array of basic, clinical, and translational research activities with annual expenditures of over $325M. Dr. Johnson received his undergraduate and medical degrees from the University of North Carolina at Chapel Hill, followed by a pediatric residency and infectious diseases training at Vanderbilt University.
Joseph W. La Barge is currently the Senior Vice President of Business Administration and General Counsel of Spark Therapeutics, Inc. Mr. La Barge is a seasoned executive and legal advisor with over fifteen years of experience counseling life science companies and healthcare institutions. Mr. La Barge was the vice president, general counsel and chief compliance officer at Tengion, Inc., a clinical-stage, regenerative medicine company, where he oversaw legal affairs, compliance and quality assurance. Mr. La Barge was previously of counsel at Ballard Spahr LLP in Philadelphia where he advised biotechnology companies in private and public financings, M&A and collaboration and licensing transactions. Mr. La Barge also served as the deputy general counsel to the Kennedy Health System in New Jersey. Mr. La Barge received his J.D. from Temple University and a B.A. from Bucknell University.
Robert Smith is Senior Vice President, Worldwide Business Development at Pfizer Inc. He is an accomplished biopharmaceutical executive with over thirty years’ experience in a variety of academic, alliance management, business development, commercial, corporate, and research and development roles. Mr. Smith is currently responsible for leading and managing the Worldwide Business Development activities for Pfizer’s Worldwide Research and Development organization. He is also responsible for leading and managing Pfizer’s Strategic Transactions team. Mr. Smith obtained a B.S. in Neuroscience from the University of Rochester and an MBA in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester.
Perry J. Sternberg is Senior Vice President and Head of the Neuroscience Business Unit at Shire– which generates more than one-third of the Company’s nearly $5B in annual sales. In this role, Mr. Sternberg is responsible for driving the optimum performance of the business unit’s product portfolio for the betterment of patients. Mr. Sternberg has over twenty years of industry experience holding positions at Merck and Co., Novartis, and Bausch & Lomb, Inc. Mr. Sternberg received a B.S. in Animal Science from The Pennsylvania State University.
Jennifer Strong is an audit partner in KPMG’s Pharmaceutical, Life Sciences practice in the Philadelphia office. Mrs. Strong has over seventeen years of public accounting experience and significant experience with revenue recognition and debt and equity issues. Mrs. Strong spent much of her career working with entrepreneurs in various emerging growth and venture back companies. She has been involved with initial and secondary public offerings as well as debt financings and private equity transactions. Mrs. Strong received her B.S. degree from Rutgers University.
Michael Yang is President, Immunology for Janssen Biotech, Inc. A dedicated and passionate business leader, Mr. Yang is committed to transformational medical innovation on behalf of patients living with chronic autoimmune diseases. In his current role, he is responsible for the overall achievement of business objectives and accelerating growth strategies for the U.S. Immunology franchise. Mr. Yang serves as a member of the North America Leadership Team (NALT) and is based in Horsham, PA. Mr.Yang earned a B.S. degree in Marketing & Business Administration from San Diego State University.
About Pennsylvania Bio
Pennsylvania Bio is the state-wide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is the global leader in the life sciences by creating a cohesive community that unites our biotechnology, medical device, diagnostic, pharmaceutical, research, and financial strengths. For more information, visit http://www.pabio.org.
SOURCE: Pennsylvania Bio